Nothing Special   »   [go: up one dir, main page]

CO5680437A2 - Derivados de pirazol-e- imidazo-pirimidina - Google Patents

Derivados de pirazol-e- imidazo-pirimidina

Info

Publication number
CO5680437A2
CO5680437A2 CO06032493A CO06032493A CO5680437A2 CO 5680437 A2 CO5680437 A2 CO 5680437A2 CO 06032493 A CO06032493 A CO 06032493A CO 06032493 A CO06032493 A CO 06032493A CO 5680437 A2 CO5680437 A2 CO 5680437A2
Authority
CO
Colombia
Prior art keywords
hydrogen
alkyl
substituted
cycloalkyl
unsubstituted
Prior art date
Application number
CO06032493A
Other languages
English (en)
Inventor
Jurgen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5680437A2 publication Critical patent/CO5680437A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula I en la que A es =C(R4)-,D es =C (R5)-, E es =C (R6)-, o uno de A, D y E es =N-, L es =N- o =C(H)-, M es =C(R7)-, cuando L es =N-; o M es =N-, cuando L es =C(H)-, Q es CF3 o CHF2, R1 es -CN, piridinilo sin sustituir, piridinilo sustituido por alquilo C1-C4 o por alcanol C1-C4 o es el correspondiente N-óxido de piridina, R2 es hidrógeno, halógeno, alquilo C1-C4 o cicloalquilo C3-C6, R3 es hidrógeno, halógeno, alquilo C1-C4 o cicloalquilo C3-C6, R4 es hidrógeno, halógeno, alquilo C1-C4 sin sustituir o alquilo C1-C4 sustituido por flúor, alcoxi C1-C4 sin sustituir o alcoxi C1-C4 sustituido por flúor, cicloalquilo C3-C6 sin sustituir o cicloalquilo C3-C6 sustituido por flúor, R5 es hidrógeno, halógeno, alquilo C1-C4 sin sustituir o alquilo C1-C4 sustituido por flúor, cicloalquilo C3-C6 sin sustituir o cicloalquilo C3-C6 sustituido por flúor, R6 es hidrógeno o halógeno, y R7 es hidrógeno, alquilo C1-C4 sin sustituir o alquilo C1-C4 sustituido por CN, cicloalquilo C3-C6 sin sustituir o cicloalquilo C3-C6 sustituido por CN, con la condición de que cuando A es =C(R4)-, D es =C(H)-, E es =C(H)-, L es =N-, R1 es -CN, R2 es hidrógeno, R3 es hidrógeno, y (a) M es =C(H)-, R4 no es hidrógeno, cloro o metoxi; o (b) M es =C(CH3)-, R4 no es hidrógeno, y sus sales de adición farmacéuticamente aceptables.
CO06032493A 2003-10-03 2006-04-03 Derivados de pirazol-e- imidazo-pirimidina CO5680437A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078075 2003-10-03

Publications (1)

Publication Number Publication Date
CO5680437A2 true CO5680437A2 (es) 2006-09-29

Family

ID=34486287

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06032493A CO5680437A2 (es) 2003-10-03 2006-04-03 Derivados de pirazol-e- imidazo-pirimidina

Country Status (21)

Country Link
US (2) US7329662B2 (es)
EP (1) EP1670801B1 (es)
JP (1) JP4551402B2 (es)
KR (2) KR100781469B1 (es)
CN (2) CN101239981B (es)
AR (1) AR045959A1 (es)
AT (1) ATE512148T1 (es)
AU (1) AU2004283801B2 (es)
BR (1) BRPI0414948A (es)
CA (1) CA2540768C (es)
CO (1) CO5680437A2 (es)
ES (1) ES2364753T3 (es)
HK (1) HK1099302A1 (es)
IL (1) IL174512A0 (es)
MX (1) MXPA06003526A (es)
NO (1) NO20061363L (es)
NZ (1) NZ546037A (es)
RU (1) RU2350616C2 (es)
TW (1) TWI297691B (es)
WO (1) WO2005040171A1 (es)
ZA (1) ZA200602677B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
AU2005254657B2 (en) 2004-06-21 2011-03-17 F. Hoffmann-La Roche Ag Pyrrazolo-pyrimidine derivatives
CN101115755B (zh) 2005-02-11 2013-01-16 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
PL1863818T3 (pl) 2005-03-23 2010-08-31 Hoffmann La Roche Pochodne acetylenylo-pirazolo-pirymidyny jako antagoniści MGLUR2
ATE463495T1 (de) 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
EP2178375B1 (en) * 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Pyrazoloý1,5-a¨pyrimidine derivatives
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
CA2880299A1 (en) * 2012-07-27 2014-01-30 Bial - Portela & Ca, S.A. Process for the synthesis of substituted urea compounds
JP2015534993A (ja) 2012-10-23 2015-12-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffma 自閉症性障害の処置のためのmGlu2/3アンタゴニスト
CA2898294C (en) 2013-02-21 2020-06-09 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
CN104193745B (zh) * 2014-07-30 2016-09-28 斯芬克司药物研发(天津)股份有限公司 一种咪唑并嘧啶羧酸类化合物及其制备方法
WO2016016382A1 (en) * 2014-08-01 2016-02-04 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2016087489A1 (en) 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv Radiolabelled mglur2 pet ligands
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
WO2017087778A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
US11033641B2 (en) 2015-12-18 2021-06-15 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 pet ligands
ES2820823T3 (es) 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados
MA51611A (fr) * 2018-01-17 2021-04-21 Glaxosmithkline Ip Dev Ltd Inhibiteurs de pi4kiiibêta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE880523T1 (de) 1996-02-07 2002-07-04 Janssen Pharmaceutica N.V., Beerse Pyrazolopyrimidine als crf rezeptor-antagonisten
EE04316B1 (et) * 1996-07-24 2004-06-15 Dupont Pharmaceuticals Company Asolotriasiinid ja -pürimidiinid, neid sisaldavadfarmatseutilised kompositsioonid ning nende kasutamine ravimite valmistamiseks
DK0891978T3 (da) 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
PL367064A1 (en) 2001-04-12 2005-02-21 F.Hoffmann-La Roche Ag Dihydro-benzo [b] [1,4] diazepin-2-one derivatives as mglur2 antagonists ii
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
CA2468067A1 (en) * 2001-11-30 2003-06-12 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine

Also Published As

Publication number Publication date
KR20070096033A (ko) 2007-10-01
HK1099302A1 (en) 2007-08-10
JP4551402B2 (ja) 2010-09-29
RU2006114749A (ru) 2007-11-20
US20050130992A1 (en) 2005-06-16
ATE512148T1 (de) 2011-06-15
IL174512A0 (en) 2006-08-01
CN101239981A (zh) 2008-08-13
CN101239981B (zh) 2011-01-19
TWI297691B (en) 2008-06-11
EP1670801B1 (en) 2011-06-08
KR20060089731A (ko) 2006-08-09
US7329662B2 (en) 2008-02-12
WO2005040171A8 (en) 2006-08-03
AR045959A1 (es) 2005-11-16
KR100781469B1 (ko) 2007-12-03
MXPA06003526A (es) 2006-06-08
CN100522964C (zh) 2009-08-05
CA2540768C (en) 2011-08-09
JP2007507446A (ja) 2007-03-29
BRPI0414948A (pt) 2006-11-07
NZ546037A (en) 2008-09-26
ES2364753T3 (es) 2011-09-13
CN1890242A (zh) 2007-01-03
EP1670801A1 (en) 2006-06-21
WO2005040171A1 (en) 2005-05-06
US20080051421A1 (en) 2008-02-28
AU2004283801B2 (en) 2010-04-22
TW200528453A (en) 2005-09-01
NO20061363L (no) 2006-04-24
RU2350616C2 (ru) 2009-03-27
ZA200602677B (en) 2007-09-26
AU2004283801A1 (en) 2005-05-06
US7514443B2 (en) 2009-04-07
CA2540768A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
CO5680437A2 (es) Derivados de pirazol-e- imidazo-pirimidina
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
NO20050870L (no) Fosfodiesterase 4-inhibitorer, inkludert N-substituerte anilin- og difenylaminanaloger
NO20054856D0 (no) 4-anilo-kinazolinderivater som antiproliferative midler
CO5540309A2 (es) Derivados de 4-(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor, la ansiedad o desordenes gastrointestinales
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
EP1490371A4 (en) TRICYCLIC COMPOUNDS BASED ON THIOPENE AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
ES2193990T3 (es) Derivados de purina.
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
TW200716575A (en) 1,3,5-triazine derivative, method for producing the same, and organic electroluminescent device containing the same as component
DE602006009080D1 (de) 1-essigsäureindolderivate mit pgd2-antagonistischer wirkung
NO20054425L (no) Heteroarylkarbamoylbenzenderivater
RS53342B (en) DERIVATIVES OF PRIVATE AND INHIBITORIES MEK
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
EP1854789A4 (en) QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
SG165361A1 (en) Antituberculous composition comprising oxazole compounds
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
WO2008136444A1 (ja) 縮合複素環誘導体
WO2005053403A3 (en) The use of n-arylhydrazine derivatives for combating non-crop pests
CY1106692T1 (el) Παραγωγα του αλοξενοϋλ-κυκλοπροπαν-1-καρβοξυλικου οξεος
MXPA04009476A (es) Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
ATE388147T1 (de) Thiazolderivate als a2b-antagonisten

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed